Key result
Transcatheter PFO closure cuts recurrent stroke ~61% vs medical therapy but increases new-onset AF.
Why the study?
The effectiveness of transcatheter PFO closure versus medical therapy for recurrent cryptogenic stroke prevention has been debated due to mixed RCT results, prompting an updated analysis incorporating newly published RCT evidence.
Does transcatheter PFO closure reduce recurrent stroke in patients with cryptogenic stroke and PFO compared to medical therapy?
Meta-Analysis (n=4,539)
Does transcatheter PFO closure reduce recurrent stroke in patients with cryptogenic stroke and PFO compared to medical therapy?
Relative Risk: 0.39 (95% CI 0.21–0.72)
p-value: p=0.003
Transcatheter PFO closure is superior to medical therapy for preventing recurrent stroke in patients with cryptogenic stroke, particularly those with an atrial septal aneurysm, though it increases the risk of new-onset atrial fibrillation.
Supports PFO closure in selected cryptogenic stroke patients; confirms RCT efficacy while highlighting need for AF monitoring.
The effectiveness of transcatheter patent foramen ovale (PFO) closure versus medical therapy for preventing recurrent strokes in cryptogenic stroke patients with PFO has been debated, with previous randomized controlled trials (RCTs) yielding mixed results. This meta-analysis was conducted to address these inconsistencies and include new evidence from a recently published RCT, offering updated insights into the efficacy and safety of these treatment strategies. We systematically searched PubMed, Scopus, and Ovid databases through December 2024. Eligible RCTs comparing PFO closure and medical therapy in cryptogenic stroke were included. The risk ratios (RR) with 95% confidence interval (CI) were computed, and P < 0.05 was considered as a level of significance. We performed subgroup analyses based on the presence of atrial septal aneurysm. Statistical analyses were performed using RevMan 5.3 (The Cochrane Collaboration, London, UK). Seven RCTs with 4,539 patients were included. PFO closure reduced recurrent stroke risk (RR: 0.39; 95% CI: 0.21-0.72; P = 0.003). No differences were found for transient ischemic attack (TIA), mortality, or bleeding. PFO closure increased the risk of new-onset atrial fibrillation (RR: 5.14; 95% CI: 2.93-9.01; P < 0.00001). Subgroup analysis showed a significant reduction in stroke with PFO closure in patients with an aneurysm (RR: 0.47; 95% CI: 0.26-0.88; P = 0.02), but not without (RR: 0.72; 95% CI: 0.47-1.11; P = 0.13). Transcatheter PFO closure demonstrates superior efficacy compared to medical therapy alone in reducing the risk of recurrent cryptogenic stroke.
No takes yet. Share an insight, caveat, or question.
Almuzainy et al. (2025) conducted a meta-analysis in Cryptogenic stroke with patent foramen ovale (n=4,539). Transcatheter patent foramen ovale (PFO) closure vs. Medical therapy (antiplatelet and/or anticoagulant therapy) was evaluated on Recurrent stroke (RR 0.39, 95% CI 0.21-0.72, p=0.003). Transcatheter PFO closure reduced the risk of recurrent stroke by 61% compared to medical therapy alone (RR 0.39, p=0.003), but increased the risk of new-onset atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: